Get the Stockscreener App
3.22
1.58%
0.05
Oramed Pharmaceuticals Inc stock is traded at $3.22, with a volume of 99,815.
It is up +1.58% in the last 24 hours and down -8.52% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$3.17
Open:
$3.15
24h Volume:
99,815
Relative Volume:
0.42
Market Cap:
$128.16M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
29.27
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
-0.92%
1M Performance:
-8.52%
6M Performance:
+55.56%
1Y Performance:
+45.05%
1-Day Range:
$3.15
$3.29
1-Week Range:
$3.13
$3.36
52-Week Range:
$1.82
$3.71
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.22 | 126.17M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal - TipRanks
Scilex Grants Oramed New Warrant in Financing Agreement - TipRanks
What is the target price for Oramed Pharmaceuticals Inc. stockEarnings Risk Report & Low Risk High Win Rate Stock Picks - mfd.ru
Is Oramed Pharmaceuticals Inc. stock a smart retirement pickJuly 2025 Trade Ideas & AI Driven Price Predictions - mfd.ru
What are analysts’ price targets for Oramed Pharmaceuticals Inc.Quarterly Earnings Summary & Daily Entry Point Trade Alerts - mfd.ru
Will Oramed Pharmaceuticals Inc. (OJU1) stock recover faster than industryJuly 2025 Gainers & Precise Swing Trade Entry Alerts - mfd.ru
Aug Setups: What drives Oramed Pharmaceuticals Inc.’s stock priceJuly 2025 Outlook & Safe Entry Point Identification - mfd.ru
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 57.8% in January - MarketBeat
Geopolitics Watch: Can Oramed Pharmaceuticals Inc keep up with sector leaders2025 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Is Oramed Pharmaceuticals Inc. stock undervalued right nowWeekly Gains Report & Safe Capital Investment Plans - mfd.ru
Support Test: Should you avoid Oramed Pharmaceuticals Inc stock right now2025 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Will Oramed Pharmaceuticals Inc. (OJU1) stock test record highs in 2025Weekly Earnings Recap & Reliable Momentum Entry Alerts - mfd.ru
Can Oramed Pharmaceuticals Inc. maintain sales growthJuly 2025 Levels & Real-Time Stock Price Movement Reports - mfd.ru
What drives Oramed Pharmaceuticals Inc.’s stock priceDividend Hike & Accurate Trade Setup Notifications - mfd.ru
What hedge funds are buying Oramed Pharmaceuticals Inc.2025 Winners & Losers & Verified Momentum Stock Alerts - mfd.ru
Lifeward Ltd. announced that it has received $0.525 million in funding - marketscreener.com
Aug Outlook: How much upside does Bakkt Holdings Inc Equity Warrant haveRecession Risk & Growth Focused Stock Pick Reports - baoquankhu1.vn
Bull Bear: What is the target price for Oramed Pharmaceuticals Inc. stockSwing Trade & Intraday High Probability Alerts - mfd.ru
NNDM stock in focus: Nano Dimension pops a poison pill days after Oramed stake build-up - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) & Demant A/S (OTCMKTS:WILYY) Head to Head Analysis - Defense World
Pullback Watch: Is Oramed Pharmaceuticals Inc stock a smart retirement pickQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
What is the next catalyst for Oramed Pharmaceuticals Inc.July 2025 Sentiment & Stock Portfolio Risk Control - mfd.ru
Swing Trade: What is Oramed Pharmaceuticals Incs 5 year growth outlookJuly 2025 Market Mood & Breakout Confirmation Trade Signals - baoquankhu1.vn
Oramed Pharmaceuticals Achieves 60.85% Return, Leading Market Performance - Markets Mojo
OraTech to pioneer oral insulin with $75 million investment - MSN
Oramed Pharm completes warrant sale, boosting liquidity - MSN
NNDM Stock In Focus: Nano Dimension Pops A Poison Pill Days After Oramed Stake Build-Up - Stocktwits
Aug Update: What is ReTo Eco Solutions Incs book value per shareJuly 2025 Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Jobs Data: Is Oramed Pharmaceuticals Inc stock good for income investors2025 Historical Comparison & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Oramed Shares Face Pressure Amid Strategic Pivot and Dividend Focus - AD HOC NEWS
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest - MarketBeat
Published on: 2026-01-17 10:34:33 - baoquankhu1.vn
Oramed Pharmaceuticals Inc.: - marketscreener.com
Oramed Pharm pivots with Lifeward strategic platform deal - TipRanks
Oramed Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Oramed to transfer oral drug delivery platform to Lifeward By Investing.com - Investing.com Nigeria
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal - Investing.com Nigeria
Buyout Rumor: Can Oramed Pharmaceuticals Inc maintain sales growthQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Oramed And Lifeward Reveal Strategic Deal - Pulse 2.0
Oramed to transfer oral drug delivery platform to Lifeward - Investing.com India
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal By Investing.com - Investing.com South Africa
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - manilatimes.net
Oramed and Lifeward Announce Strategic Transaction - Financial Times
Lifeward Ltd. announced that it expects to receive $20 million in funding from Oramed Pharmaceuticals Inc. - marketscreener.com
Oramed Announces Shareholder Capital Return Following Strategic Windfall - AD HOC NEWS
Take Profit: Will Oramed Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Intraday Action & Growth Focused Investment Plans - Улправда
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oramed Pharmaceuticals Inc Stock (ORMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kidron Miriam | Chief Scientific Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
1,448,664 |
| Gabay Avraham | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
649,256 |
| KIDRON NADAV | President and CEO |
Jan 22 '26 |
Option Exercise |
0.00 |
109,000 |
0 |
3,355,238 |
0.34%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):